CN109125631A - Chinese medicine composition and preparation method thereof with liver kidney regulatory function - Google Patents
Chinese medicine composition and preparation method thereof with liver kidney regulatory function Download PDFInfo
- Publication number
- CN109125631A CN109125631A CN201811342832.6A CN201811342832A CN109125631A CN 109125631 A CN109125631 A CN 109125631A CN 201811342832 A CN201811342832 A CN 201811342832A CN 109125631 A CN109125631 A CN 109125631A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- liver kidney
- medicine composition
- regulatory function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine compositions with liver kidney regulatory function, each component including following parts by weight: 3-30 parts of lophatherum gracile, pueraria lobata 5-50,0.5-20 parts of witloof, 30-70 parts of mulberry leaf, 50-100 parts of emblic, 30-80 parts of dried orange peel, smilax 20-80,20-80 parts of the eggplant base of a fruit, the invention further relates to a kind of preparation methods of said medicine, including pulverize and sieve, and mix and powder processed.Chinese medicine composition raw material provided by the invention with liver kidney regulatory function are cheap and easily-available, liver kidney can be adjusted after taking, and long-time service can reduce Uric Acid level and the significant effect duration is long, additionally it is possible to improve immunity of organisms.
Description
Technical field
The invention belongs to field of Chinese medicinal composition, and in particular to a kind of Chinese medicine composition with liver kidney regulatory function and its
Preparation method.
Background technique
The intracorporal uric acid of people is there are about 1200 milligrams, and newly-generated about 600 milligrams daily, while 600 milligrams are drained, in flat
The state of weighing apparatus.Since present many human diets are not scientific, living habit is irregular, it is easier to there is high lithemia phenomenon, and it is old
People is the main foreigner tourists of high lithemia disease since the body function of itself is weaker.Excessive uric acid is generated in vivo to have little time to drain or urinate
Sour excretion mechanism is degenerated, then internal uric acid is detained excessive, when blood uric acid concentration is greater than 7 milligrams/deciliter, human body fluid is caused to become
Acid, influences the normal function of human body cell, and gout will be caused for a long time by ignoring.Hyperuricemia patients illness initial stage belongs to no disease
Shape hyperuricemia is not in the clinical symptoms such as arthritis, high lithemia stone or kidney stone.Only blood test can just find blood
Uric acid concentration is high.But when the uric acid of hypersaturated state forms acicular crystal deposits in knuckle synovia, it can lead to acute height
Urarthritis.More seriously urate crystal is deposited on kidney and causes lesion, can cause uric acid nephropathy (i.e. pain
Wind nephrosis).
Gout is to be generated excessive due to uric acid or cause uric acid in blood to increase because uric acid excretion is bad, urate crystal deposition
The caused repeated relapsing arthritis disease in synovium of joint, synovial bursa, cartilage and its hetero-organization, this is a kind of lifelong participation disease
Disease.The patient with gout of absent renal function damage or joint deformity, normal life and work can generally be maintained by effectively being treated, less
It will affect the service life.But if malpractice, the recurrent exerbation of acute arthritis can cause larger pain.There are joint deformity and nephrolith
Then quality of life will receive certain influence to patient.Kidney function damage serious person, curative effect is poor, so once finding the state of an illness
It to treat as early as possible.The urarthritis of untreated, its severity and the speed of development also have very big difference.Some patients
All one's life only breaks out several times, however most of if do not treated, with breaking-out repeatedly, frequency and degree be in gradual exacerbation.Have
The service life that people counts patient with gout is 5 years short compared with ordinary person, but this effect completely with the situation of individual and treatment has relationship.Work as joint
Cartilage disappear, subchondral bone matter corrode and periarticular tissue infiltration, when causing gradual invalid, a small number of severe persons several years it
It is interior, that is, it can produce the serious destruction in huge tophus and joint.Influencing Most patients life is due to kidney and angiocarpy
The presence of the complication such as disease.
In the selection for inhibiting uric acid high, mainly there are two methods of western medicine and Chinese medicine treatment.Western medicine has uricosuric row
Benzbromarone, probenecid and the drug for inhibiting uric acid to generate let out have allopurinol, these poisonous side effect of medicine are big, long-term consumption
Secondary injury can be caused to body.Medically being badly in need of one kind takes safety at present, treats effective drug for adjusting internal urine
Acid, so the natural drug for selecting some toxic side effects small as far as possible carrys out anti-trioxypurine.
Although now there are many by adjusting hepatic and renal function to reduce the important composition thing of uric acid, equal raw material and
Production technology is complicated, and effect duration is short.
Summary of the invention
To solve problems of the prior art, the present invention provides a kind of Chinese medicine composition with liver kidney regulatory function
And preparation method thereof, each component including following parts by weight: 3-30 parts of lophatherum gracile, pueraria lobata 5-50,0.5-20 parts of witloof, mulberry leaf
30-70 parts, 50-100 parts of emblic, 30-80 parts of dried orange peel, smilax 20-80,20-80 parts of the eggplant base of a fruit.
Preferably, each component including following parts by weight: 10-20 parts of lophatherum gracile, pueraria lobata 25-30, witloof 10-12
Part, 40-50 parts of mulberry leaf, 70-75 parts of emblic, 40-60 parts of dried orange peel, 35-55 parts of smilax, 35-55 parts of the eggplant base of a fruit.
The present invention also provides a kind of preparation methods of Chinese medicine composition with liver kidney regulatory function, according to sequencing
The following steps are included:
Step (1): raw material is pulverized and sieved, the raw material after weighing sieving in proportion；
Step (2): weighed sieving raw material is added to the mixer and is sufficiently mixed；
Step (3): the dosage form taken is made in the material mixed addition auxiliary material.
Preferably, the raw material includes: lophatherum gracile powder, kudzu-vine root powder, witloof powder, mulberry leaf powder, emblic leafflower powder, tangerine peel powder,
Smilax powder, eggplant base of a fruit powder.
In any of the above-described scheme preferably, the raw material includes Herba Lophatheri extract, kudzu root extract, witloof extraction
Object, mulberry-leaf extract, emblic extract, dried orange peel extracts, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.
In any of the above-described scheme preferably, in step (1), the sieve pore of the sieve for selection of being sieved is 100 mesh.
In any of the above-described scheme preferably, in step (3), the dosage form is pulvis.
In any of the above-described scheme preferably, this law is used to prepare the above-mentioned Chinese traditional medicine composition with liver kidney regulatory function
Object and preparation method thereof.
Henon bamboo blade root is medicinal, there is refrigerant, antipyretic, diuresis and the benefits of hasten parturition；The major functions: in the heart disease heat, cough with dyspnea, haematemesis,
Heat toxin wind, only quench one's thirst, press borax poison, dissolving phlegm, control it is fanatical unhappiness, apoplectic aphasia in silence, pain intermittent headache, stop palpitate with fear, pestilence be confused it is bored, kill
Small worm delays spleen except hot.
Pueraria lobata has expelling pathogenic factors from muscles and skin to bring down a fever, and promoting eruption promotes the production of body fluid to quench thirst, the function of Shengyang Zhixie.It is usually used in exterior syndrome fever, stiff nape and back, fiber crops
Rash is impermeable, and pyreticosis is thirsty, and the deficiency of Yin is quenched one's thirst, and heat is purged heat dysentery, splenasthenic diarrhea.
Witloof has clearing heat and detoxicating, inducing diuresis to remove edema, stomach invigorating and other effects.
Mulberry leaf mulberry leaf are the dried leafs of moraceae plants mulberry.It is harvested after first frost, removes impurity, dry and obtain, be a kind of diverging
Wind-heat medicine, both oral administration, can also be applied with.Its is cold in nature, sweet in flavor, bitter, there is the effect of dispelling wind and heat from the body, clearing away the lungheat and moisturizing, clear liver and improve vision, can
Treat anemopyretic cold, lung-heat type cough, dizziness headache, the illness of red eyes and dim-sighted
Emblic fruit is rich in vitamin C abundant, edible, can promote the production of body fluid to quench thirst, moistening lung for removing phlegm controls cough, larynx
Bitterly, globefish poisoning etc. is solved.First food flavor is sour and astringent, be for a good while it is sweet, it is therefore named " emblic ".Tree root and leaf hyoscine, the antipyretic detoxicating of energy,
Control dermatitis, eczema, rheumatalgia etc..
Dried orange peel regulating qi-flowing for strengthening spleen is eliminating dampness and eliminating phlegm.For abdominal fullness and distention, deficiency of food is vomited and diarrhoea, coughing with a lot of sputum.
Smilax Chang Yuxia, the excavation of two season of autumn, remove fibrous root, and drying is used as medicine after cleaning；Or take advantage of after fresh-cut flakiness it is dry,
It is used as medicine.It is sweet in flavor, light, it is mild-natured.Have removing toxic substances, dehumidify, it is easing joint movement the effect of, be mainly used for limbs caused by syphilis and mercury poisoning arrest
Contraction, arthralgia and myalgia；Damp and hot stranguria with turbid discharge, leukorrhagia, carbuncle swells, scrofula, scabies.
The eggplant base of a fruit has the effect of cool blood, removing toxic substances.It is usually used in discharging fresh blood stool, carbuncle swells, boil on the nape, toothache.
Chinese medicine composition raw material provided by the invention with liver kidney regulatory function are cheap and easily-available, can be to liver after taking
Kidney is adjusted, and long-time service can reduce Uric Acid level and the significant effect duration is long, additionally it is possible to improve body
Immunity.
Specific embodiment
In order to be further understood that summary of the invention of the invention, the present invention is elaborated below in conjunction with specific embodiment.
Embodiment one
Raw material proportioning: 3 parts of lophatherum gracile, 5 parts of pueraria lobata, 0.5 part of witloof, 30 parts of mulberry leaf, 50 parts of emblic, 30 parts of dried orange peel, soil
20 parts of Poria cocos, 20 parts of the eggplant base of a fruit；
Preparation method: former material used is sieved, and is extracted by Herba Lophatheri extract needed for raw material proportioning accurate weighing, pueraria lobata
Object, chicory extract, mulberry-leaf extract, emblic extract, dried orange peel extracts, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Embodiment two
Raw material proportioning: 10 parts of lophatherum gracile, 25 parts of pueraria lobata, 10 parts of witloof, 40 parts of mulberry leaf, 70 parts of emblic, 40 parts of dried orange peel, soil
35 parts of Poria cocos, 35 parts of the eggplant base of a fruit；
Preparation method: former material used is sieved, and is extracted by Herba Lophatheri extract needed for raw material proportioning accurate weighing, pueraria lobata
Object, chicory extract, mulberry-leaf extract, emblic extract, dried orange peel extracts, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Embodiment three
Raw material proportioning: 16 parts of lophatherum gracile, 27 parts of pueraria lobata, 10 parts of witloof, 45 parts of mulberry leaf, 75 parts of emblic, 55 parts of dried orange peel, soil
50 parts of Poria cocos, 50 parts of the eggplant base of a fruit；
Preparation method: former material used is sieved, and is extracted by Herba Lophatheri extract needed for raw material proportioning accurate weighing, pueraria lobata
Object, chicory extract, mulberry-leaf extract, emblic extract, dried orange peel extracts, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Example IV
Raw material proportioning: 20 parts of lophatherum gracile, pueraria lobata 30,12 parts of witloof, 50 parts of mulberry leaf, 75 parts of emblic, 60 parts of dried orange peel, native Fu
55 parts of Siberian cocklebur, 55 parts of the eggplant base of a fruit；
Preparation method: former material used is sieved, and is extracted by Herba Lophatheri extract needed for raw material proportioning accurate weighing, pueraria lobata
Object, chicory extract, mulberry-leaf extract, emblic extract, dried orange peel extracts, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Embodiment five
Raw material proportioning: 30 parts of lophatherum gracile, pueraria lobata 50,20 parts of witloof, 70 parts of mulberry leaf, 100 parts of emblic, 80 parts of dried orange peel, soil
Poria cocos 80,80 parts of the eggplant base of a fruit；
Preparation method: former material used is sieved, and is extracted by Herba Lophatheri extract needed for raw material proportioning accurate weighing, pueraria lobata
Object, chicory extract, mulberry-leaf extract, emblic extract, dried orange peel extracts, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Animal experiment
The pharmaceutical composition (embodiment 1-5) for facilitating uric acid adjusting of five different dosage forms has been configured to sterile water
The solution that concentration is 10mg/mL is imitated, convenient for administration.
Material: Bioengineering Research Institute is built up in uric acid detection kit, Nanjing.
After normal male Kunming mouse overnight fasting, following eight groups are randomly divided by weight, normal group, model group, control
Treat 1 group, 2 groups for the treatment of, 3 groups for the treatment of, 4 groups for the treatment of, 5 groups for the treatment of, 6 groups, every group 8 for the treatment of.Normal group gives basal feed nursing,
Model group and treatment 1-5 group give high yeast feed (+80 basal feed of 20% yeast extract)+200mg/kg Oteracil Potassium, cause
Hyperuricemia model.Treatment 1-5 group is injected intravenously embodiment 1 respectively while modeling, embodiment 2, embodiment 3, implements
Example 4, embodiment 5, drug solution (dosage once a day 1mL/100g), normal group and model group are injected intravenously equivalent
Physiological saline.Successive administration 4 weeks.At the end of medication the 0th, 1,2,4 week, in batches after administration 3 hours, eyeball takes blood 0.5mL,
It after standing 1 hour at room temperature, is centrifuged 20 minutes under 3000rpm revolving speed, serum uric acid detection kit is taken to measure uric acid water
It is flat.Experimental result is as shown in table 1 after counting.
The variation (μm ol/L) of the serum uric acid level of 1 each group of table
Compared with model group, P < 0.05 *.
The Serum experiments data of 1 model group of analytical table are it is found that the model group serum uric acid raising when testing 1 week, at the 2nd week
Reach peak, it is still more much higher than normally organizing data although the 4th week serum uric acid level is declined, illustrate that the height is urinated
Acidaemia model has continuous stability, designs very successful.It treats serum uric acid value of the 1-5 group at the 1st week and has reached peak,
But the numerical value (P < 0.05) of respectively less than model group.At the 2nd week, the uric acid level for the treatment of 1-5 group declines to a great extent, and controls within the 4th week
The uric acid level for treating 1-5 group is no different with normal group.It to sum up analyzes, illustrates that the embodiment herbal composite for treating 1-5 group all has
Inhibit uric acid to be formed, promotes uric acid excretion, reduce the effect of serum uric acid.
Clinical test
Effect of the invention is further described in detail below with reference to the clinical test that hospital carries out.
150 hyperuricemia patients are divided into six groups, take embodiment 1, embodiment 2, embodiment 3, embodiment 4, reality respectively
The Chinese medicine composition of example 5 is applied, in the morning, afternoon and evening each 1 time daily, is continuously taken 30 days.Detect the uric acid water before and after patient on medication
It is flat, the curative effect of herbal composite of the present invention is judged with this, table 2 is therapeutic effect of each embodiment to human body hyperuricemia.
Therapeutic effect of each embodiment of table 2 to hyperuricemia
From the data of table 2 it is found that six embodiment drugs are significant to the therapeutic effect of hyperuricemia, treated effect
Greater than 96%.During clinical test and the concrete condition of patient is tracked.
Curative effect monitoring
So that this 150 hyperuricemia patients pauses is used Chinese medicine composition provided by the invention, measured patient's every 15 days
Uric acid level monitors the lasting effect of herbal composite of the present invention with this.Table 3 is curative effect monitoring situation.
Lasting effect of 3 present invention of table to hyperuricemia
As known from Table 3, Chinese medicine composition provided by the invention uric acid level just meeting after 45 days that patient cuts out
Rise, illustrates that the significant in efficacy and duration of Chinese medicine composition is long.
It will be apparent to those skilled in the art that of the invention Chinese medicine composition and its preparation side with liver kidney regulatory function
Method includes the summary of the invention and specific embodiment part of aforementioned present invention specification, as space is limited and to keep specification concise
Each scheme that these combinations are constituted is not described one by one.Any modification for all within the spirits and principles of the present invention, being made,
Equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (8)
1. a kind of Chinese medicine composition with liver kidney regulatory function, each component including following parts by weight: 3-30 parts of lophatherum gracile,
Pueraria lobata 5-50,0.5-20 parts of witloof, 30-70 parts of mulberry leaf, 50-100 parts of emblic, 30-80 parts of dried orange peel, smilax 20-80, the eggplant base of a fruit
20-80 parts.
2. the Chinese medicine composition according to claim 1 with liver kidney regulatory function, which is characterized in that including following weight
The each component of number: 10-20 parts of lophatherum gracile, pueraria lobata 25-30,10-12 parts of witloof, 40-50 parts of mulberry leaf, 70-75 parts of emblic, old
40-60 parts of skin, 35-55 parts of smilax, 35-55 parts of the eggplant base of a fruit.
3. a kind of preparation method of the Chinese medicine composition with liver kidney regulatory function, according to sequencing the following steps are included:
Step (1): raw material is pulverized and sieved, the raw material after weighing sieving in proportion；
Step (2): weighed sieving raw material is added to the mixer and is sufficiently mixed；
Step (3): the dosage form taken is made in the material mixed addition auxiliary material.
4. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney regulatory function, which is characterized in that institute
Stating raw material includes: lophatherum gracile powder, kudzu-vine root powder, witloof powder, mulberry leaf powder, emblic leafflower powder, tangerine peel powder, smilax powder, eggplant base of a fruit powder.
5. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney regulatory function, which is characterized in that institute
Stating raw material includes Herba Lophatheri extract, kudzu root extract, chicory extract, mulberry-leaf extract, emblic extract, dried orange peel extraction
Object, Rhizoma Smilacis Glabrae extract, eggplant base of a fruit extract.
6. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney regulatory function, which is characterized in that step
Suddenly in (1), the sieve pore of the sieve for selection of being sieved is 100 mesh.
7. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney regulatory function, which is characterized in that step
Suddenly in (3), the dosage form is pulvis.
8. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney regulatory function, which is characterized in that use
The Chinese medicine composition and preparation method thereof with liver kidney regulatory function described in preparation any one of claims 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811342832.6A CN109125631A (en) | 2018-11-13 | 2018-11-13 | Chinese medicine composition and preparation method thereof with liver kidney regulatory function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811342832.6A CN109125631A (en) | 2018-11-13 | 2018-11-13 | Chinese medicine composition and preparation method thereof with liver kidney regulatory function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109125631A true CN109125631A (en) | 2019-01-04 |
Family
ID=64805715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811342832.6A Pending CN109125631A (en) | 2018-11-13 | 2018-11-13 | Chinese medicine composition and preparation method thereof with liver kidney regulatory function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109125631A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141638A (en) * | 2019-05-30 | 2019-08-20 | 江西虔农农业股份有限公司 | A kind of Chinese medicine composition and application for improving gout |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139887A3 (en) * | 2006-05-22 | 2008-05-08 | Cargill Inc | Methods for treating bone or joint inflammation |
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN105876777A (en) * | 2016-04-12 | 2016-08-24 | 周安琪 | Food having effect of reducing uric acid and preparation technology thereof |
| CN108403987A (en) * | 2018-05-11 | 2018-08-17 | 刘松松 | One kind preventing antipodagric witloof jasmine tea |
-
2018
- 2018-11-13 CN CN201811342832.6A patent/CN109125631A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139887A3 (en) * | 2006-05-22 | 2008-05-08 | Cargill Inc | Methods for treating bone or joint inflammation |
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN105876777A (en) * | 2016-04-12 | 2016-08-24 | 周安琪 | Food having effect of reducing uric acid and preparation technology thereof |
| CN108403987A (en) * | 2018-05-11 | 2018-08-17 | 刘松松 | One kind preventing antipodagric witloof jasmine tea |
Non-Patent Citations (1)
| Title |
|---|
| 徐蕾等: "《常见病中医临床经验丛书 痛风中医特色疗法》", 30 June 2012, 人民军医出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141638A (en) * | 2019-05-30 | 2019-08-20 | 江西虔农农业股份有限公司 | A kind of Chinese medicine composition and application for improving gout |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109172670A (en) | Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function | |
| CN104758404B (en) | A kind of three snake compound powder of compound and preparation method thereof | |
| CN109172770A (en) | Facilitate the herbal composite and preparation method thereof of uric acid adjusting | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN105194341B (en) | The drug for treating xerostomia after head and neck neoplasm radiotherapy | |
| CN105031408B (en) | A kind of composition improving gout | |
| CN110859904A (en) | Gorgon fruit oral liquid capable of tonifying kidney, supporting yang, tonifying qi and producing sperm | |
| CN109125631A (en) | Chinese medicine composition and preparation method thereof with liver kidney regulatory function | |
| CN104706839A (en) | Traditional Chinese medicine preparation for treating rheumatic arthritis | |
| CN105497701A (en) | Natural medicine for treating gout diseases and preparation method thereof | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN108578607A (en) | A kind of pharmaceutical composition for treating kidney stone | |
| CN115554372B (en) | Traditional Chinese medicine for treating primary fibromyalgia syndrome and preparation method and application thereof | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN102008072B (en) | Blood pressure lowering edible wild herb food therapy composition | |
| CN107137689A (en) | A kind of Chinese medicine composition for treating menopausal syndrome | |
| CN109419844B (en) | Tibetan medicine composition for treating osteoarthritis pain | |
| CN106421534A (en) | Traditional Chinese medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN104547091B (en) | It is a kind of to treat medicine of Osteoarthritis and preparation method thereof | |
| TWI260226B (en) | Complex prescription of Chinese medicine for the treatment of extensive cancer | |
| CN105288396A (en) | Traditional Chinese medicine for treating qi stagnation and blood stasis type primary osteoporosis and preparation method thereof | |
| CN104815023A (en) | Traditional Chinese medicine composition for treating kidney yin deficiency type chronic cervicitis | |
| CN104667194A (en) | Heat-clearing and detoxifying agent for chronic pneumonia and preparation method of heat-clearing and detoxifying agent | |
| CN104306585A (en) | Traditional Chinese medicine combination for curing prostatitis, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190104 |